Surface Oncology (Surface Oncology) Capex-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Surface Oncology's Capital Expenditure for the three months ended in Jun. 2023 was $0.00 Mil. Its Revenue for the three months ended in Jun. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Surface Oncology Capex-to-Revenue Historical Data

The historical data trend for Surface Oncology's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology Capex-to-Revenue Chart

Surface Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Capex-to-Revenue

Get a 7-Day Free Trial

0.03

0.10

0.05

0.02

Surface Oncology Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Capex-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Surface Oncology's Capex-to-Revenue

For the Biotechnology subindustry, Surface Oncology's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surface Oncology's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surface Oncology's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Surface Oncology's Capex-to-Revenue falls into.

Surface Oncology Capex-to-Revenue Calculation

Surface Oncology's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.497)	/	30
	=	0.02

Surface Oncology's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Surface Oncology (NAS:SURF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Surface Oncology Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Surface Oncology's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Surface Oncology (Surface Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139

Website

https://www.surfaceoncology.com

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.

Executives

Chandra Adams	officer: Deputy GC	SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill	officer: Chief Medical Officer
Jessica Fees	officer: See Remarks	C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross	officer: Chief Medical Officer	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath	officer: Chief Business Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella	officer: Chief Scientific Officer	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn	director	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey	director	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater	director, officer: Chief Executive Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p.	10 percent owner	46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc	10 percent owner	56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118